BRNS
Barinthus Biotherapeutics plcNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.31
P/S
0.00
EV/EBITDA
0.61
DCF Value
$1.48
FCF Yield
-206.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-70.6%
ROA
-67.7%
ROIC
-59.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-11.1M | $-0.27 |
| FY 2025 | $0.00 | $-66.4M | $-1.64 |
| Q3 2025 | $0.00 | $-14.6M | $-0.36 |
| Q2 2025 | $0.00 | $-21.1M | $-0.52 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
GB
Exchange
NASDAQ
Beta
-0.60
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.